This association of non-functional p53 with sensitivity of Plk1 inhibition leads to the second assumption that inactive p53 facilitates the cytotoxicity of Plk1 inhibition and tumor patients with p53 deficiency/mutation may preferentially benefit from treatment with Plk1 inhibitors. Here, TP53 is linked to neoplasm.